Chapter 1
Tissue engineering tries to grow or rebuild functional tissue by combining three things: a supporting structure, living cells, and a controlled environment in which the two mature together. WIA-BIO-006 (version 1.0.0, status Active, published 2025-12-26 by the WIA Biomedical Engineering Research Group) gives that practice a common vocabulary, a set of design equations, and machine-readable records. A scaffold designed in one laboratory can then be understood, tested, and reproduced in another. This chapter introduces the standard's scope, the physical quantities it relies on, the data records it defines, and the tools that implement it.
The standard defines a framework for scaffold design, biofabrication, cell culture, and quality assurance in regenerative medicine. Its scope covers natural, synthetic, and hybrid biomaterial scaffolds, 3D bioprinting techniques and protocols, bioreactor design and operation, vascularization and perfusion strategies, and quality control with regulatory compliance. The guiding principle is 弘益人間 (Benefit All Humanity): regenerative medicine that restores health and is accessible to all.
The headline capabilities are:
Five terms recur throughout the book, and the specification defines them as follows.
| Term | Meaning in WIA-BIO-006 |
|---|---|
| Scaffold | Three-dimensional structure that supports cell attachment and tissue formation |
| Bioprinting | Additive manufacturing process that uses living cells |
| Bioreactor | Device providing a controlled environment for tissue culture |
| ECM | Extracellular matrix, the natural scaffold produced by cells |
| Decellularization | Removing cells while preserving the ECM structure |
The definitions set up the central design question of the field. A scaffold has to be strong enough to hold its shape, open enough for cells and nutrients to move through it, and bioactive enough for cells to attach. It also has to degrade on roughly the timescale at which the body replaces it with new tissue. Most of the standard's numbers serve one of these four demands.
Three structural quantities describe a scaffold's openness. Porosity is the fraction of the scaffold volume that is void. It can be computed directly from volumes or, when only density is known, from apparent density against the density of the solid material. Average pore diameter is derived from void volume and pore surface area. Interconnectivity is the share of pores that are connected to their neighbors. Isolated pores trap cells and block nutrient flow, so the specification sets a minimum interconnectivity of 90%.
P = (V_void / V_total) × 100%
P = (1 - ρ_apparent / ρ_material) × 100%
d_pore = 6 × V_void / S_pore
I = (N_connected / N_total) × 100%
σ = F / A₀ ε = ΔL / L₀ E = σ / ε
D = N_cells / V_scaffoldThe last line is cell seeding density, covered in the next section. The stress-strain relations are the compression test: a known force on the initial cross-sectional area gives stress, the change in length gives strain, and their ratio gives Young's modulus. The specification recommends different porosity and pore-size windows for different tissues, because each cell type needs a different amount of room.
| Tissue | Recommended porosity | Cell type | Optimal pore size |
|---|---|---|---|
| Bone | 60–80% | Osteoblasts | 100–400 μm |
| Cartilage | 70–85% | Fibroblasts | 50–150 μm |
| Skin | 80–95% | Endothelial cells | 30–100 μm |
| Liver | 85–90% | Hepatocytes | 20–50 μm |
The porosity and pore-size columns are independent lists in the standard, not row-for-row pairs. Pore size is keyed to cell type, porosity to tissue. A scaffold for a vascularized tissue may therefore need to satisfy both an endothelial pore window and a bulk-tissue porosity window.
Material choice sets the mechanical and degradation envelope. The standard tabulates the common candidates, and its full text adds alginate (ionically cross-linked with Ca²⁺ or Ba²⁺, gelling instantaneously, 10–100 kPa), polyglycolic acid (about 7 GPa, 2–4 weeks degradation) and hybrids such as 70% PCL with 30% collagen.
| Material | Young's modulus | Porosity range | Degradation | Biocompatibility |
|---|---|---|---|---|
| Collagen | 1–10 MPa | 70–95% | 2–8 weeks | Excellent |
| PCL | 200–400 MPa | 60–80% | 6–24 months | Good |
| PLA | 2000–4000 MPa | 50–90% | 6–12 months | Good |
| Gelatin | 0.1–1 MPa | 80–95% | 1–4 weeks | Excellent |
| Chitosan | 1–2 GPa | 70–90% | 4–12 weeks | Excellent |
Reading this table against the tissue targets in the specification shows why composites exist. Bone is listed at 10–20 GPa, and no polymer in the table reaches that range. Cartilage at 0.5–2 MPa overlaps the lower end of collagen. Liver, at 0.5–1 kPa, is softer than any scaffold material listed here, and cardiac tissue at 10–50 kPa is also soft. Collagen is bioactive, with RGD domains for cell adhesion, but mechanically weak. PCL is strong and slow to degrade but hydrophobic. The PCL–collagen composite is the standard's example of trading one property for another, offering a tunable degradation rate and improved cell adhesion at a modulus of 50–150 MPa. The gelatin–alginate blend, with dual thermal and ionic gelation, serves soft, injectable applications.
A scaffold is only half a construct. The standard recognizes three families of cell source. Primary cells keep the native phenotype and tissue-specific function, but they expand poorly and vary between donors. Stem cells (ESCs, MSCs and iPSCs) are differentiated with tissue-specific growth factors and mechanical cues. Cell lines such as NIH 3T3, HepG2, and MC3T3 offer unlimited supply and reproducibility.
Getting cells into a scaffold is a measurable step with its own efficiency, and the standard documents four seeding methods.
| Method | Essence of the protocol | Efficiency |
|---|---|---|
| Static | 10⁶–10⁷ cells/mL pipetted onto scaffold, 2–4 h attachment | 20–50% |
| Dynamic (spinner flask) | Rotation at 50 rpm for 4–8 h, then static culture | 40–70% |
| Vacuum | 50–100 kPa for 5–10 min, then release to draw cells into pores | 60–90% |
| Centrifugal | 100–500 ×g for 5–10 min | 70–95% |
For centrifugation the standard gives RCF = 1.12 × r × (RPM/1000)², with the radius in millimetres. Target densities depend on tissue: bone 5 × 10⁶ to 2 × 10⁷ cells/cm³, cartilage 2 × 10⁷ to 6 × 10⁷ cells/cm³, liver 5 × 10⁷ to 2 × 10⁸ cells/cm³, and skin 1 × 10⁶ to 5 × 10⁶ cells/cm². Optimal density is expressed as a function of tissue type, scaffold porosity and culture duration, so the porosity of the scaffold feeds into how many cells should be loaded.
The Phase 1 data format turns all of this into five structured records, called envelopes:
The envelopes are cross-referenced on purpose. A bioink headed for regulatory submission points to the Phase 4 regulatory envelope, and a tissue-specific architecture points to the Phase 3 target-tissue envelope. A reader can then follow a construct from material choice to regulatory pathway without leaving the record.
The specification does not publish market sizes, and none are quoted here. The demand for a shared format can still be read from the standard's own use cases. Skin grafts, cartilage repair, bone regeneration and cardiac patches are therapeutic applications. Drug testing and disease modeling use engineered tissue as a research tool, and organ transplantation is the long-term goal. These customers want different things from the same technology, and each needs trustworthy data about what a scaffold or bioink is.
The recurring cost in this field is poorly comparable data. A modulus reported without its test geometry, a porosity reported without its method, or a cell batch without donor and passage information cannot be reproduced or audited. The standard addresses this by making these fields mandatory parts of a record. A therapeutic developer, a contract manufacturer and a pharmaceutical screening team can then exchange constructs under the same definitions.
The standard lists seven use cases, and each draws on a different part of the specification:
Quality in this standard is anchored to existing, widely used documents. Scaffold characterization follows ASTM F2150, and ISO 13314 compression testing is applied by analogy to polymeric scaffolds. Sterility is tested per USP <71>, endotoxin per USP <85> (below 0.5 EU/mL for cell sources), and mycoplasma freedom is referenced to USP <63>. Cytotoxicity follows ISO 10993-5, and implantation biocompatibility follows ISO 10993-6. Reports must cite the controlling ISO, ASTM or USP document, so a pass/fail flag is always traceable to its criterion.
Five quality considerations apply across every application. All materials and processes must stay sterile. Cell viability after seeding must be at least 80%. Mechanical properties must match the native tissue within 20%. Degradation must be controlled to follow the regeneration timeline. Immune response after implantation should be minimal. The compliance layer is a single signature-and-provenance mechanism, the chain-of-custody hash and analyst signature already described, and the standard's technical weight lies in these domain tests.
The reference implementation is the TypeScript package @wia/bio-006 plus a command-line tool, wia-bio-006. The SDK exposes four design-and-validation functions: designScaffold, optimizeCulture, assessMechanicalProperties and validateBiocompatibility. A shortened cartilage example from the specification shows how a scaffold object feeds a culture simulation:
import { designScaffold, optimizeCulture } from '@wia/bio-006';
const scaffold = designScaffold({
tissueType: 'cartilage',
material: 'pcl-collagen',
porosity: 75,
poreSize: 200, // micrometers
dimensions: { length: 10, width: 10, height: 3 }
});
const culture = optimizeCulture({
tissueConstruct: scaffold,
cellType: 'chondrocytes',
flowRate: 0.5, // mL/min
oxygenLevel: 5, // %
temperature: 37 // °C
});
console.log(culture.predictedMaturation, culture.qualityScore);The same operations are available from the shell:
wia-bio-006 design-scaffold --tissue cartilage --material pcl --porosity 75
wia-bio-006 optimize-culture --cell-type chondrocytes --duration 21
wia-bio-006 assess-mechanics --force 100 --area 0.0001
wia-bio-006 validate-biocompat --material collagen --cell-type fibroblastsNote that the output of designScaffold is passed directly to optimizeCulture. The scaffold is a first-class object that carries its volume, surface area and estimated cell capacity, and the culture step reasons from those properties.
Several practical points follow for adopters:
The specification's own structure shows where it is heading. It has an organ-on-chip capability, a cross-referenced regulatory phase, and a telemetry-oriented API for bioreactors. These suggest a shift from isolated, manually documented experiments toward continuously recorded production, where culture conditions are logged as they happen. The architecture descriptor already lists complex pore topologies such as gyroid and octet truss. These are shapes that bioprinting can make and conventional fabrication cannot, so the format is prepared for designs well beyond simple porous blocks.
The integration with simulation tools points the same way. Predicted maturation and quality scores from optimizeCulture are early examples of design-time forecasting. As more complete records accumulate, those forecasts can be checked against measured outcomes in the quality-test envelope. The standard does not claim this will happen on a particular schedule, but its data model is built to support it.
WIA-BIO-006 treats tissue engineering as a chain of measurable decisions. Porosity, pore diameter, interconnectivity and Young's modulus are computed from stated formulas. Material, cell source and seeding method are chosen against tissue-specific windows. Five linked records (scaffold, bioink, architecture, cell source and quality test) capture the result, each tied to ASTM, ISO or USP test documents. The TypeScript SDK and CLI let the design equations run on those records, and the quality criteria (sterility, at least 80% viability, mechanics within 20% of native tissue, controlled degradation, minimal immunogenicity) keep every construct measurable against its purpose.
The next chapter takes up the first link in that chain, scaffold materials and design. It covers the natural biomaterials (collagen, gelatin, chitosan, alginate) and the synthetic polymers (PCL, PLA, PGA) in detail, shows how hybrids combine their strengths, and works through the porosity, pore-size and mechanical-testing calculations introduced here on realistic examples.